Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Genertec Universal Medical Group Company Limited (2666.HK)
Beijing, CN
Genertec Universal Medical Group Company Limited, founded in 1984 and based in Beijing, China, provides extensive financing and advisory services across the People's Republic of China, alongside operating a significant healthcare business. The company's operations are segmented into two primary divisions. The Finance and Advisory segment delivers a range of services including direct finance leasing, sale-and-leaseback arrangements, factoring, operating leases, and various advisory offerings. Meanwhile, its Hospital Group segment focuses on providing medical care, managing hospitals and healthcare facilities, and conducting import, export, and general trading of medical-related goods. Beyond these core areas, Genertec Universal Medical also engages in medical technology development, hospital digitalization, construction, and management services, as well as property management and medical consulting. The company serves a diverse clientele, encompassing patients, hospitals, medical equipment suppliers, and other public sector organizations. In July 2018, the company adopted its current name, having previously operated as Universal Medical Financial & Technical Advisory Services Company Limited.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.58% | -4.08% | -10.86% | -15.38% | -17.41% | -13.11% | -3.18% | +9.53% | -27.08% | -4.79% | +3.40% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Financial - Credit Services: +13.2%+6.4% Q4'25: +2.0% (vs Q4'23)
-
EPS growth Financial - Credit Services: +24.0%+5.9% Q4'25: +2.2% (vs Q4'23)
-
FCF margin FCF growth · Financial - Credit Services: +70.9%+21.9% Q4'25: +27.5% (vs Q4'23)
-
EBIT margin Financial - Credit Services: +28.7%+21.2% Q4'25: +28.2% (vs Q4'23)
-
ROIC Financial - Credit Services: +5.0%+3.4% Q4'25: +8.6% (vs Q4'23)
-
Share dilution Financial - Credit Services: +0.0%+0.1% Q4'25: -2.8% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Financial - Credit Services: 4.07×12.92× Q4'25: 5.18× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.20B
est: 2.28B (-3.8%)
|
2.71B
est: 3.11B (-12.9%)
|
3.42B
est: 4.16B (-17.8%)
|
4.30B
est: 4.88B (-12.0%)
|
6.75B
est: 8.03B (-16.0%)
|
8.24B
est: 10.20B (-19.2%)
|
9.57B
est: 13.37B (-28.5%)
|
11.57B
est: 12.70B (-8.9%)
|
13.65B
est: 12.28B (+11.1%)
|
13.66B
est: 13.66B (0.0%)
|
14.54B
est: 14.61B (-0.5%)
|
15.64B
15.64B – 15.64B
+7.0% YoY
|
16.02B
16.02B – 16.02B
+2.4% YoY
|
16.59B
16.59B – 16.59B
+3.6% YoY
|
| EBITDA |
-1.40M
est: 650.90M (-100.2%)
|
1.23B
est: 1.31B (-6.4%)
|
1.60B
est: 1.43B (+12.5%)
|
1.89B
est: 1.48B (+27.7%)
|
2.36B
est: 2.33B (+1.6%)
|
2.67B
est: 3.00B (-11.3%)
|
3.04B
est: 3.46B (-12.2%)
|
3.18B
est: 4.50B (-29.2%)
|
3.41B
est: 3.37B (+1.4%)
|
3.56B
est: 3.73B (-4.6%)
|
3.88B
est: 4.00B (-3.2%)
|
4.29B
4.29B – 4.29B
+7.0% YoY
|
4.39B
4.39B – 4.39B
+2.4% YoY
|
4.55B
4.55B – 4.55B
+3.6% YoY
|
| EBIT |
848.53M
est: 566.18M (+49.9%)
|
1.21B
est: 1.29B (-6.5%)
|
1.58B
est: 1.40B (+12.6%)
|
1.86B
est: 1.45B (+27.8%)
|
2.22B
est: 2.29B (-2.8%)
|
2.40B
est: 2.90B (-17.5%)
|
2.72B
est: 3.35B (-18.7%)
|
2.74B
est: 4.35B (-37.0%)
|
2.91B
est: 2.86B (+1.7%)
|
2.96B
est: 3.17B (-6.6%)
|
3.09B
est: 3.40B (-9.1%)
|
3.64B
3.64B – 3.64B
+7.0% YoY
|
3.73B
3.73B – 3.73B
+2.4% YoY
|
3.86B
3.86B – 3.86B
+3.6% YoY
|
| Net Income |
658.53M
est: 940.60M (-30.0%)
|
872.31M
est: 943.77M (-7.6%)
|
1.15B
est: 1.01B (+13.4%)
|
1.35B
est: 1.06B (+27.6%)
|
1.59B
est: 1.66B (-4.5%)
|
1.75B
est: 2.08B (-15.9%)
|
1.95B
est: 2.39B (-18.7%)
|
1.96B
est: 1.89B (+3.5%)
|
2.11B
est: 2.04B (+3.4%)
|
2.10B
est: 2.23B (-5.8%)
|
2.21B
est: 2.25B (-2.0%)
|
2.34B
2.32B – 2.35B
+3.6% YoY
|
2.44B
2.40B – 2.47B
+4.3% YoY
|
2.58B
2.58B – 2.58B
+5.7% YoY
|
| SGA |
460.42M
est: 275.18M (+67.3%)
|
554.48M
est: 659.86M (-16.0%)
|
523.82M
est: 643.81M (-18.6%)
|
631.60M
est: 588.14M (+7.4%)
|
846.00M
est: 776.79M (+8.9%)
|
994.26M
est: 1.11B (-10.1%)
|
1.20B
est: 1.28B (-5.8%)
|
1.36B
est: 1.66B (-18.1%)
|
1.57B
est: 1.49B (+5.1%)
|
1.71B
est: 1.65B (+3.4%)
|
1.80B
est: 1.77B (+1.7%)
|
1.90B
1.90B – 1.90B
+7.0% YoY
|
1.94B
1.94B – 1.94B
+2.4% YoY
|
2.01B
2.01B – 2.01B
+3.6% YoY
|
| EPS |
0.44
est: 0.47 (-6.0%)
|
0.51
est: 0.58 (-11.7%)
|
0.67
est: 0.78 (-13.9%)
|
0.79
est: 0.91 (-13.5%)
|
0.87
est: 0.93 (-6.3%)
|
0.96
est: 1.34 (-28.3%)
|
0.99
est: 1.33 (-25.3%)
|
1.00
est: 1.11 (-9.9%)
|
1.07
est: 1.01 (+5.6%)
|
1.07
est: 1.11 (-3.6%)
|
1.13
est: 1.12 (+0.9%)
|
1.16
1.15 – 1.17
+3.6% YoY
|
1.21
1.19 – 1.23
+4.3% YoY
|
1.28
1.28 – 1.28
+5.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-05-28 | A | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-05-27 | A | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-05-26 | A | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-05-22 | A | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-05-21 | A | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-05-20 | A | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-05-19 | A | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-05-18 | A | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-05-15 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-05-14 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-05-13 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-05-12 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-05-05 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-05-04 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 4/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Dividend ETF EDIV | 0.49% | 6.06M | 0.49% |
| 2 | First Trust Emerging Markets Small Cap AlphaDEX Fund FEMS | 0.38% | 960.6K | 0.80% |
| 3 | iShares MSCI China Small-Cap ETF ECNS | 0.35% | 228.8K | 0.59% |
| 4 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.06% | 460.0K | 0.65% |
| 5 | iShares Ageing Population UCITS ETF AGED.L | 0.06% | 552.5K | 0.40% |
| 6 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.06% | 68.9K | 0.42% |
| 7 | FlexShares Morningstar Emerging Markets Factor Tilt Index Fund TLTE | 0.05% | 181.9K | 0.58% |
| 8 | iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L | 0.04% | 30.3K | 0.74% |
| 9 | iShares MSCI Emerging Markets Small-Cap ETF EEMS | 0.04% | 132.2K | 0.72% |
| 10 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.03% | 92.7K | 0.74% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Qi Xia | Chief Executive Officer & Executive Director | 3M | male |
| Wang Wenbing | Chief Executive Officer & Executive Director | 3M | male |
| Lin Wang | Executive Director | 3M | female |
| Shisu Chen | Executive Chairman | 3M | male |
| Shinan Wang | Chief Accounting Officer & Chief Compliance Officer | — | female |
| Feng Qingming | Chief Medical Officer | — | male |
| Wai Kam Ng | Company Secretary | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2666.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
